Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 3, 2008, Pages 397-399

  Raffa, Jesse D ^a   Tossonian, Harout K ^a   Grebely, Jason ^a   Petkau, A John ^a   Devlaming, Stanley ^b   Conway, Brian ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Pender Community Health Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; METHADONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

AGE DISTRIBUTION; ANTIVIRAL RESISTANCE; GENE MUTATION; GENOTYPE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; SHORT COURSE THERAPY; VIRUS LOAD; ADULT; BLOOD; CANADA; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; FEMALE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDY; STATISTICS; THEORETICAL MODEL; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; METHADONE; MIDDLE AGED; MODELS, THEORETICAL; MUTATION; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 42449084610     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815b0d35     Document Type: Letter

References (6)

1. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS. 1999;13(Suppl 1):S61-S72.
2. Bangsberg DR, Porco TC, Kagay C, et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis. 2004;190:162-165.
3. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistancemutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.
4. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis. 2005;191:2046-2052.
5. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis. 2004;38(Suppl 5):S402-S408.
6. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med. 2005;13:125-131.